At 11 hospitals across Spain, researchers flipped the script on how doctors manage blood pressure in the hours after stroke thrombectomy—and the results are reshaping what's possible in stroke recovery. The HOPE clinical trial, officially the Hemodynamic Optimization of Cerebral Perfusion after Endovascular Therapy, demonstrated that personalizing blood pressure targets based on how well each patient's brain tissue is actually being perfused after the procedure leads to significantly better outcomes, without triggering the complications doctors feared.
Why this matters cuts to the heart of a stubborn paradox in modern stroke care. Mechanical thrombectomy, which physically removes blood clots from major brain vessels, has revolutionized treatment for large-vessel occlusion strokes. Yet roughly half of patients who achieve technically successful reperfusion—their blocked artery is reopened on imaging—still don't recover well. This phenomenon, called "clinically ineffective reperfusion," reflects a harsh reality: reopening a vessel doesn't guarantee the brain tissue will actually get the blood it needs. Reperfusion injury, microcirculatory dysfunction, loss of cerebral autoregulation, and hemorrhagic transformation can all sabotage recovery even after a procedure goes perfectly on paper. As Dr. Pol Camps-Renom, head of the Cerebrovascular Diseases Research Group at IR Sant Pau and a study coordinator, explains it: "Many times we can reopen the artery, but the brain tissue does not respond as expected."
The breakthrough in HOPE was moving beyond the one-size-fits-all strategies of previous trials. Instead of applying uniform blood pressure targets to every patient, the researchers adapted their approach to each person's actual reperfusion status. For patients with near-complete or complete reperfusion, doctors used lower blood pressure targets to minimize reperfusion injury. Those with incomplete reperfusion were maintained at higher levels to preserve what blood flow they had. This recognition—that diverse brains need diverse hemodynamic states—required close monitoring during the first 72 hours after thrombectomy, with treatment adjusted dynamically based on what imaging and physiology revealed.
The study enrolled 440 patients across the 11 hospitals and randomly assigned them either to this tailored strategy or to conventional management. The results were decisive. At 90 days, 60.0% of patients in the personalized blood pressure group achieved functional independence—the ability to manage daily activities—compared with 47.1% in the standard care group. That 13.3 percentage point difference is not just statistically significant; it represents 53 additional patients walking toward genuine recovery out of every 440 treated. Critically, the individualized approach did not increase complications, including hemorrhagic stroke, the very risk that had made doctors cautious about aggressive interventions.
"Until now, we have applied fairly uniform strategies after thrombectomy, but probably not all patients need the same approach," Camps-Renom says. "Our results suggest that adjusting blood pressure according to the degree of reperfusion can have a direct impact on recovery."
Presented at the European Stroke Organization's annual conference and published in JAMA Neurology, HOPE positions this work among the most significant recent contributions to stroke medicine. The findings have immediate clinical potential to guide hemodynamic management protocols globally, moving the field closer to a future where every stroke patient receives treatment calibrated to their brain's actual physiological needs rather than a standardized template.